Safe and Efficacious Use of Low‐Dose Rituximab in Postpubertal Paediatric Patients With Immune Thrombocytopenia
ABSTRACT Background Rituximab, a CD20 monoclonal antibody, is used in chronic/refractory immune thrombocytopenia (ITP). Standard dosing is 375 mg/m2 weekly for 4 weeks alongside dexamethasone. A lower dose of Rituximab at 100 mg weekly demonstrates comparable efficacy that is well tolerated. This st...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | eJHaem |
| Online Access: | https://doi.org/10.1002/jha2.70010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | ABSTRACT Background Rituximab, a CD20 monoclonal antibody, is used in chronic/refractory immune thrombocytopenia (ITP). Standard dosing is 375 mg/m2 weekly for 4 weeks alongside dexamethasone. A lower dose of Rituximab at 100 mg weekly demonstrates comparable efficacy that is well tolerated. This study evaluates lower‐dose Rituximab with dexamethasone in postpubertal pediatric ITP patients. Methods Patients treated with 100 mg weekly Rituximab for 4 weeks alongside dexamethasone at 10 mg/m2 on days 1–5 and 21–25 were assessed for response and safety. Results Of the 10 patients treated, six responded completely, one partially and three showed no response. Four responders maintained their response over 2 years. One Rituximab‐related infusion reaction and one Dexamethasone‐related adverse event were reported. Conclusion Rituximab 100 mg weekly may be non‐inferior to 375 mg/m2 weekly for paediatric patients. |
|---|---|
| ISSN: | 2688-6146 |